PTGX FDA approves MIMRYLO for erythrocytosis in PV
PTGX says the FDA has approved MIMRYLO for erythrocytosis in PV, described as first-in-class with a broadly labeled therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.